Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report details a specific share repurchase transaction executed on October 7, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 150,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,375 pence per share; lowest price paid was 1,364 pence per share.
- Treasury Holdings (Settled): 505,796,816 shares (9.08% of total issued share capital).
- Treasury Holdings (Including Unsettled): 506,276,370 shares (10.00% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,063,676,535 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 150,000 shares for Treasury. This transaction increased the Company's Treasury holdings to exactly 10.00% of the current total voting rights when including shares purchased but not yet settled.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,063,676,535) for calculating disclosure thresholds under FSA rules.
- Confirm the Treasury share percentage (10.00% of voting rights) for assessing potential dilution or buyback program status.
- Note that this filing does not contain operational or financial performance data for the period.